Cynthia A. Challener

As an important method for improving the stability of parenterals, lyophilization is fairly well understood, but can still benefit from several advancements in the technology.

Iterative and multiple incremental advances in particle-characterization technology are making a difference in pharmaceutical analysis applications.

With high productivity achieved, makers of cell-culture media are working to optimize product quality through better understanding and control of raw materials and production processes.

The trick to taste-masking in solid dosage forms is to never let the taste buds have a chance.

Russell Madsen, group leader of the Parenteral Drug Association (PDA) Filtration Interest Group, discusses technical and regulatory considerations in filtration for parenteral drug manufacturing

It can take up to two weeks or more to obtain results from traditional microbiological testing methods. Rapid, automated testing can reduce that time in half.

Although the use of biocatalysis for asymmetric transformations is growing, chemocatalysis remains a highly competitive technology.

Equipment suppliers are helping the pharmaceutical industry move towards adoption of continuous tablet production.

Ensuring the quality of raw materials is a crucial component of achieving product quality of APIs and finished drug products.

Matthieu Egloff, product director with ATMI LifeSciences, discusses the need for larger, special reactors that can provide the necessary conditions for the production of fragile cells on a larger scale.

Collaboration provides pharmaceutical industry customers with access to enzyme expertise and assets resulting in cost-effective, green processing at all phases of development, from preclinical to commercial manufacturing scale.

Ultra high-pressure liquid chromatography (UHPLC) is enabling faster product development and production batch approvals with increased sensitivity.

Dow Chemical and Bend Research are developing and commercializing new materials for spray-dried dispersions that address technology gaps in manufacturability and delivery.

Matthieu Egloff, product director with ATMI LifeSciences, discusses the need for larger, special reactors that can provide the necessary conditions for the production of fragile cells on a larger scale.

The growth in biologics drugs and vaccines is leading to greater demand for prefilled syringes, which provide greater safety and convenience for healthcare workers and patients.

Custom manufacturers with expertise in highly potent API production discuss the latest issues and technology developments in the field.

New handheld Raman technology is helping improve raw-material analysis and counterfeit-drug detection.

Kevin Ott, executive director of the Bio-Process Systems Alliance, discusses the latest trends and issues surrounding single-use technologies and the role of his association.

Specially designed excipients, improvements in processing capabilities, and a growing understanding of the hot-melt extrusion (HME) process is increasing the use of HME as an approach for enhancing the bioavailability of poorly soluble drugs.

AAIPharma Services CEO Patrick Walsh talks about the parenterals market and the drivers for his company's recent expansion of its sterile-manufacturing capabilities.